Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
12/11/24 | Candel (CADL) | CAN-2409 for Prostate Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
12/10/24 | NewAmsterdam (NAMS) | Obicetrapib for Dyslipidemia / Hypercholesterolemia | Subscribers Only | Subscribers Only | Subscribers Only |
12/10/24 | Incyte (INCY) | Monjuvi for Follicular Lymphoma (FL) | Subscribers Only | Subscribers Only | Subscribers Only |
12/10/24 | CervoMed (CRVO) | Neflamapimod for Lewy Body Dementia (LBD) | Subscribers Only | Subscribers Only | Subscribers Only |
12/10/24 | Sutro Biopharma (STRO) | Luvelta for Ovarian Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
02/29/2024 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
06/30/2024 | Subscribers Only | Subscribers Only | Trial Announcement - Trial Completion (Emerging Markets) |
01/01/2025 - 06/30/2024 | Subscribers Only | Subscribers Only | Trial Data - Final Results |
09/12/2024 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
09/30/2024 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |